Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference
November 05 2020 - 9:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials
in progress poster presentation on Marzeptacog alfa (activated) –
or MarzAA, the Company’s subcutaneously administered
next-generation engineered coagulation Factor VIIa (FVIIa), at the
upcoming 62nd Annual American Society of Hematology (ASH) meeting
being held virtually December 5-8, 2020.
Poster presentation
details: |
|
|
Poster Title: |
The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and
Safety of Subcutaneous Marzeptacog Alfa (activated) for on-Demand
Treatment and Control of Bleeding Episodes in Subjects with
Hemophilia A or Hemophilia B, with Inhibitors |
Presenting Author: |
Linda Neuman, M.D., M.B.A., vice president, clinical development,
Catalyst Biosciences |
Date/Time: |
Sunday, December 6, 2020 / 7 am PT |
A copy of the presentation materials can be
accessed on the Events and Presentations section of the
Catalyst website on the day of the presentation.
MarzAA, a next-generation recombinant Factor
VIIa variant, is the only subcutaneously administered bypass agent
in development for the treatment of Hemophilia A or B with
inhibitors and other rare bleeding disorders, including Factor VII
Deficiency and Glanzmann thrombasthenia. In late 2020, Catalyst
Biosciences plans to dose the first patient in Crimson 1, its Phase
3 study of MarzAA for treatment of episodic bleeding in Hemophilia
A and B with inhibitors.
About Catalyst Biosciences
Catalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare hematologic and complement-mediated disorders. Our protease
engineering platform generated two late-stage clinical programs in
hemophilia; a research program on engineering of subcutaneous (SQ)
complement inhibitors; a discovery stage Factor IX gene therapy
construct - CB 2679d-GT - for Hemophilia B, and a partnered
preclinical development program with Biogen for dry age-related
macular degeneration (AMD). The product candidates generated by our
protease engineering platform have improved functionality and
potency that allow for: SQ administration of recombinant
coagulation factors and complement inhibitors; low-dose, high
activity gene therapy constructs; and less frequently dosed
intravitreal therapeutics.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties.
Forward-looking statements include statements about Catalyst’s
plans to enroll the first patient in a Phase 3 open-label trial of
MarzAA and initiate a Phase 1/2 trial of MarzAA in FVII Deficiency,
Glanzmann Thrombasthenia, and Hemlibra patients before year-end,
the potential for MarzAA to effectively and therapeutically treat
hemophilia subcutaneously, the superiority of CB 2679d-GT over
other gene therapy candidates and the Company’s collaboration with
Biogen for the development and commercialization of pegylated CB
2782 for the potential treatment of geographic atrophy-associated
dry age-related macular degeneration. Actual results or events
could differ materially from the plans, intentions, expectations
and projections disclosed in the forward-looking statements.
Various important factors could cause actual results or events to
differ materially, including, but not limited to, the risk that
trials and studies may be delayed as a result of COVID-19 and other
factors, that trials may not have satisfactory outcomes, that
additional human trials will not replicate the results from earlier
trials, that potential adverse effects may arise from the testing
or use of MarzAA, including the generation of neutralizing
antibodies, the risk that costs required to develop or manufacture
the Company’s products will be higher than anticipated, including
as a result of delays in development and manufacturing resulting
from COVID-19 and other factors, the risk that Biogen will
terminate Catalyst’s agreement, competition and other risks
described in the “Risk Factors” section of the Company’s quarterly
report filed with the Securities and Exchange
Commission on November 5, 2020, and in other filings with
the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024